PMID- 34693102
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231107
IS  - 2468-4511 (Print)
IS  - 2468-4511 (Electronic)
IS  - 2468-4511 (Linking)
VI  - 20
DP  - 2021 Dec
TI  - Integrating in vitro disease models of the neurovascular unit into discovery and 
      development of neurotherapeutics.
LID - 100341 [pii]
LID - 10.1016/j.cobme.2021.100341 [doi]
AB  - The blood-brain barrier (BBB) regulates the transport of small molecules, 
      proteins, and cells between the bloodstream and the central nervous system (CNS). 
      Brain microvascular endothelial cells work with other resident brain cell types, 
      including pericytes, astrocytes, neurons, and microglia, to form the 
      neurovascular unit (NVU) and maintain BBB integrity. The restrictive barrier 
      influences the pathogenesis of many CNS diseases, and impedes the delivery of 
      neurotherapeutics into the CNS. In vitro NVU models enable the discovery of 
      complex cell-cell interactions involved in human BBB pathophysiology in diseases 
      including Alzheimer's Disease (AD), Parkinson's Disease (PD) and viral infections 
      of the brain. In vitro NVU models have also been deployed to study the delivery 
      of neurotherapeutics across the BBB, including small molecule drugs, monoclonal 
      antibodies, gene therapy vectors and immune cells. The high scalability, 
      accessibility, and phenotype fidelity of in vitro NVU models can facilitate the 
      discovery and development of effective neurotherapeutics.
FAU - Ding, Yunfeng
AU  - Ding Y
AD  - Department of Chemical and Biological Engineering, University of 
      Wisconsin-Madison, Madison, WI, USA.
FAU - Shusta, Eric V
AU  - Shusta EV
AD  - Department of Chemical and Biological Engineering, University of 
      Wisconsin-Madison, Madison, WI, USA.
AD  - Department of Neurological Surgery, University of Wisconsin-Madison, Madison, WI, 
      USA.
FAU - Palecek, Sean P
AU  - Palecek SP
AD  - Department of Chemical and Biological Engineering, University of 
      Wisconsin-Madison, Madison, WI, USA.
LA  - eng
GR  - R01 NS107461/NS/NINDS NIH HHS/United States
GR  - R01 NS109486/NS/NINDS NIH HHS/United States
GR  - R33 HL154254/HL/NHLBI NIH HHS/United States
GR  - R61 HL154254/HL/NHLBI NIH HHS/United States
PT  - Journal Article
DEP - 20210915
PL  - England
TA  - Curr Opin Biomed Eng
JT  - Current opinion in biomedical engineering
JID - 101704011
PMC - PMC8530278
MID - NIHMS1741451
OTO - NOTNLM
OT  - Blood-brain barrier
OT  - Disease Modelling
OT  - Drug Delivery
OT  - Neurotherapeutic
OT  - Neurovascular unit
COIS- Disclosure/conflict of interest The authors have multiple issued patents and 
      patent applications in the field of BBB modeling.
EDAT- 2021/10/26 06:00
MHDA- 2021/10/26 06:01
PMCR- 2022/12/01
CRDT- 2021/10/25 06:44
PHST- 2021/10/25 06:44 [entrez]
PHST- 2021/10/26 06:00 [pubmed]
PHST- 2021/10/26 06:01 [medline]
PHST- 2022/12/01 00:00 [pmc-release]
AID - 100341 [pii]
AID - 10.1016/j.cobme.2021.100341 [doi]
PST - ppublish
SO  - Curr Opin Biomed Eng. 2021 Dec;20:100341. doi: 10.1016/j.cobme.2021.100341. Epub 
      2021 Sep 15.